ARVN Arvinas Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARVN

Price (delayed)

$22.72

Market cap

$1.22B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.58

Enterprise value

$1.12B

Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing ...

Highlights
Arvinas's revenue has soared by 58% YoY and by 15% from the previous quarter
The gross profit has soared by 58% YoY and by 15% from the previous quarter
The quick ratio has declined by 40% year-on-year and by 15% since the previous quarter
The company's equity fell by 31% YoY and by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://arvinas.com
Peers: OMGA

Key stats

What are the main financial stats of ARVN
Market
Shares outstanding
53.49M
Market cap
$1.22B
Enterprise value
$1.12B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.62
Price to sales (P/S)
7.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.9
Earnings
Revenue
$162.9M
EBIT
-$285.3M
EBITDA
-$277.8M
Free cash flow
-$322.7M
Per share
EPS
-$5.58
Free cash flow per share
-$6.04
Book value per share
$8.68
Revenue per share
$3.05
TBVPS
$20.29
Balance sheet
Total assets
$1.08B
Total liabilities
$619.9M
Debt
$4.5M
Equity
$463.6M
Working capital
$749.8M
Liquidity
Debt to equity
0.01
Current ratio
3.44
Quick ratio
3.42
Net debt/EBITDA
0.33
Margins
EBITDA margin
-170.5%
Gross margin
100%
Net margin
-182.7%
Operating margin
-182.5%
Efficiency
Return on assets
-24.5%
Return on equity
-55.1%
Return on invested capital
-34.6%
Return on capital employed
-36.7%
Return on sales
-175.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARVN stock price

How has the Arvinas stock price performed over time
Intraday
-1.65%
1 week
-6.89%
1 month
-13.71%
1 year
-47.08%
YTD
-33.59%
QTD
-8.46%

Financial performance

How have Arvinas's revenue and profit performed over time
Revenue
$162.9M
Gross profit
$162.9M
Operating income
-$297.3M
Net income
-$297.6M
Gross margin
100%
Net margin
-182.7%
Arvinas's revenue has soared by 58% YoY and by 15% from the previous quarter
The gross profit has soared by 58% YoY and by 15% from the previous quarter
ARVN's operating income is down by 36% YoY and by 3.1% from the previous quarter
The company's net income fell by 28% YoY

Growth

What is Arvinas's growth rate over time

Valuation

What is Arvinas stock price valuation
P/E
N/A
P/B
2.62
P/S
7.45
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.9
The EPS has contracted by 25% YoY
The stock's price to book (P/B) is 45% less than its 5-year quarterly average of 4.8 and 18% less than its last 4 quarters average of 3.2
The company's equity fell by 31% YoY and by 9% QoQ
The P/S is 85% below the 5-year quarterly average of 49.9 and 42% below the last 4 quarters average of 12.8
Arvinas's revenue has soared by 58% YoY and by 15% from the previous quarter

Efficiency

How efficient is Arvinas business performance
The company's return on invested capital has shrunk by 78% YoY and by 12% QoQ
ARVN's return on equity has dropped by 77% year-on-year and by 8% since the previous quarter
ARVN's return on assets has dropped by 60% year-on-year and by 6% since the previous quarter
The ROS has grown by 20% YoY and by 13% from the previous quarter

Dividends

What is ARVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARVN.

Financial health

How did Arvinas financials performed over time
ARVN's total assets is 75% more than its total liabilities
The quick ratio has declined by 40% year-on-year and by 15% since the previous quarter
ARVN's current ratio is down by 40% YoY and by 15% QoQ
The debt is 99% smaller than the equity
The company's equity fell by 31% YoY and by 9% QoQ
The debt has declined by 29% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.